Distinguished in Diabetic Retinopathy

Ali Erginay

Paris, FR 
Distinguished in Diabetic Retinopathy
Paris, FR 
OverviewLocationsClinical Research

Overview

Ali Erginay practices in Paris, France. Erginay is rated as a Distinguished expert by MediFind in the treatment of Diabetic Retinopathy. Their top areas of expertise are Diabetic Macular Edema (DME), Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Vitrectomy.

Their clinical research consists of co-authoring 49 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 27 articles in the study of Diabetic Retinopathy.

Locations

Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study)
Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study)
Enrollment Status: Completed
Publish Date: June 29, 2023
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.
Enrollment Status: Completed
Publish Date: December 27, 2018
Intervention Type: Procedure
Study Phase: Phase 3
View 1 Less Clinical Trial

49 Total Publications

Real-world faricimab switch in France: artificial intelligence-based detection of changes in exudative signs in difficult-to-treat neovascular age-related macular degeneration.
Real-world faricimab switch in France: artificial intelligence-based detection of changes in exudative signs in difficult-to-treat neovascular age-related macular degeneration.
Journal: BMJ open ophthalmology
Published: April 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Erginay's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile